TOPIC : Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
|Publication date:||18 December 2015|
|Types of action:||IMI2-RIA Research and Innovation action|
|DeadlineModel: Opening date:||multiple cut-off 18 December 2015||Cut-off dates:||
16 March 2016 17:00:00
15 September 2016 17:00:00
16 March 2017 17:00:00
14 September 2017 17:00:00
15 March 2018 17:00:00
|Time Zone : (Brussels time)|
20 June 2017 16:59
In order to fully address the objectives of the IMI2 Ebola+ programme as a programmatic approach addressing different challenges across the entire innovation cycle and aiming at leveraging input and multi-disciplinary expertise across stakeholders, potential applicants are also strongly encouraged to consider the opportunities offered through the Call for proposals that will be launched in parallel by the CEPI alliance (Coalition for Epidemic Preparedness Innovations http://cepi.net).
In line with the IMI2 Call 8 topic text, this would offer the foundation for constructive synergies and complementarities with other projects and initiatives focusing on preparedness to react to future outbreaks of Ebola and other filoviral haemorrhagic fevers. This would also avoid duplication of efforts and to create collaboration at a global level to maximise European added value in health research.
Topic DescriptionSpecific Challenge:
The recent outbreak of Ebola virus disease (EVD) in West Africa underscores the vulnerability of populations worldwide to pathogens such as filoviral viruses. Currently, there are no vaccines or antiviral drugs approved for prevention or treatment of filoviral infections in humans.Scope:
This Call provides an opportunity to capture emerging scientific advances and to progress those rapidly into health care interventions. Proposals may address aspects of pre-clinical development and/or Phase 1, 2, and 3 clinical developments of vaccines (in particular multivalent), treatments and diagnosis of Ebola or other filovirus infections. Manufacturing strategies, vaccine stability during transport and storage, and/or deployment of vaccines and treatments are also in scope. Proposals for the development of adaptable platforms, which in addition to filoviruses can address multiple other priority pathogens, are also eligible.Expected Impact:
Proposals must contribute to the objectives of IMI2 and in particular to the goals of the Ebola+ programme which is a programmatic approach addressing different challenges across the entire innovation cycle and aims at leveraging input and multidisciplinary expertise across stakeholders.
Specifically, proposals must increase the readiness to respond to future outbreaks of Ebola and other filoviral haemorrhagic fevers.
An important expected impact of projects funded under this Call must be to maximise the benefit to the people in the countries at risk from future outbreaks of filoviral haemorrhagic fevers. In order to achieve this, successful applicant consortia should have the capability to accelerate their project results into health care interventions.
Furthermore, proposals are expected to take advantage of and exploit support from different stakeholders with the necessary expertise, including the mobilization of funds through the inclusion of contributing partners under the IMI scheme of public-private consortia. Such contributing partners might include EFPIA companies or organizations associated to EFPIA, and Associated Partners to IMI. The budgeted cost for the participation of such partners is expected to account for at least 40% of the total project cost.
Projects are expected to have a significant impact on global health, both at the individual and the public health level by leading to results that have a direct impact for persons at risk of exposure to filoviral diseases or for patients suffering from filoviral disease.Cross-cutting Priorities:
Topic conditions and documents
Please read carefully all provisions below before the preparation of your application :
You can access the full description of the topic in the Call topic text.
The budget breakdown for this Call is given in the Call Conditions section at the end of the Call topic text (page 9) as well as the following information :
- List of countries and applicable rules for funding
- Eligibility and admissibility conditions
- Evaluation criteria and procedure, scoring and threshold: described in the IMI Manual for Submission, Evaluation adn Grant award
- Indicative timetable for evaluation and grant agreement
- Provisions, proposal templates and evaluation forms for the type of action under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
|Type of Action||Research and Innovation action [IMI2-RIA]|
|Topic||Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks - IMI2-2015-08-01|
|Guidance on proposal submission:||H2020 online manual|
Contact the IMI Progamme Office : E-mail : email@example.com
Contact the Participant Portal Helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc...
IMI States Representative Group (SRG) – contact you SRG member for assistance.
IMI Partner Seach Tool - find a partner organisation for your proposal
National Contact Points (NCP) - contact your NCP for further assistance.
Enterprise Europe Network - contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
Research Enquiry Service - ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular
Ethics - to ensure compliance with ethical issues, check the information available on the Participant Portal, on the Sciences and Society Portal and in the European Charter for Researchers and the Code of Conduct for their recruitment